Patent Frameworks For AI-Assisted Bioengineering In Medical Therapeutics.
I. Core Patentability Requirements in AI-Bioengineering
Across jurisdictions (U.S., Europe, India, etc.), the core patentability requirements are:
Patentable Subject Matter
Novelty
Inventive Step / Non-Obviousness
Enablement and Sufficiency
Industrial Applicability / Utility
However, AI-assisted therapeutics raise unique doctrinal tensions:
Is an AI algorithm an abstract idea?
Is a genetically engineered molecule a “product of nature”?
Can AI be an inventor?
Are treatment methods patentable?
To understand how courts handle these questions, we examine major case laws.
II. Foundational Case Laws Shaping AI-Bioengineering Patents
1. Diamond v. Chakrabarty
Background
Ananda Chakrabarty genetically engineered a bacterium capable of breaking down crude oil. The USPTO rejected the patent claim, arguing living organisms are not patentable.
Supreme Court Holding
The Court held that:
“Anything under the sun that is made by man” is patentable.
Legal Principle Established
Genetically modified organisms (GMOs) are patentable
The key distinction is between:
Products of nature ❌
Human-made inventions ✅
Relevance to AI-Assisted Bioengineering
This case underpins:
Patents on AI-designed engineered cells
AI-optimized gene edits
Synthetic proteins created using machine learning
If AI assists in designing a novel therapeutic microorganism, the human-engineered nature of the organism remains patentable under Chakrabarty principles.
2. Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Background
The patent claimed a method of optimizing drug dosage based on measuring metabolite levels in the blood.
Holding
The Court invalidated the patent, stating:
Laws of nature (correlation between metabolite level and efficacy) are not patentable.
Merely adding routine steps does not transform it into patentable subject matter.
Legal Rule
Introduced a two-step test:
Is the claim directed to a law of nature?
Does it contain an “inventive concept” sufficient to transform it?
Impact on AI-Bioengineering
This case severely affects:
AI diagnostic models
Personalized medicine algorithms
Biomarker-based therapeutic predictions
If an AI model discovers that Gene X correlates with Drug Y response, the correlation alone is not patentable.
But a specific engineered therapeutic application may be.
3. Association for Molecular Pathology v. Myriad Genetics, Inc.
Background
Myriad patented isolated BRCA1 and BRCA2 genes related to breast cancer risk.
Holding
Naturally occurring DNA sequences are not patentable
Complementary DNA (cDNA), synthetically created, is patentable
Key Principle
Discovery ≠ Invention
Isolation of natural DNA ≠ patentable
Synthetic modification = patentable
Application to AI-Bioengineering
AI systems that:
Identify disease genes → not patentable per se
Create novel synthetic gene constructs → patentable
For example:
AI-discovered mutation pattern ❌
AI-designed synthetic therapeutic vector ✅
This case is central for AI-guided gene editing, CRISPR optimization, and mRNA therapeutics.
4. Alice Corp. v. CLS Bank International
Background
Alice patented a computerized financial settlement method.
Holding
The Court ruled:
Abstract ideas implemented on a computer are not patentable.
Introduced the modern §101 two-step test (building on Mayo).
The Alice Test
Is the claim directed to an abstract idea?
Does it contain “something more” that transforms it?
Relevance to AI in Therapeutics
AI-assisted bioengineering patents must avoid:
Claiming “a machine learning model configured to predict drug efficacy” in purely functional terms.
Instead, patents should:
Claim specific technical architectures
Link algorithmic steps to concrete biological transformation
Claim engineered therapeutic outputs
Thus, AI-based therapeutic inventions must demonstrate technical improvement, not just abstract computation.
5. Ariosa Diagnostics, Inc. v. Sequenom, Inc.
Background
The patent covered detection of fetal DNA in maternal blood for prenatal diagnosis.
Holding
The Federal Circuit invalidated the patent:
The discovery of cell-free fetal DNA is a natural phenomenon.
Applying routine detection techniques did not add inventive concept.
Significance
Even groundbreaking discoveries can fail patent eligibility if they:
Merely apply conventional techniques to natural phenomena.
AI Context
If AI discovers:
A novel biomarker present in plasma
That discovery alone is not patentable unless:
The claimed method includes innovative technical implementation.
6. Harvard College v. Canada (Commissioner of Patents)
Background
Harvard sought a patent for the “Oncomouse,” genetically engineered to develop cancer for research.
Holding
The Supreme Court of Canada ruled:
Higher life forms are not patentable in Canada.
Importance
Different jurisdictions treat biotech inventions differently.
Relevance to AI-Bioengineering
AI-engineered animals:
Patentable in U.S.
Possibly restricted in Canada
This highlights the importance of jurisdiction-specific strategy.
7. Thaler v. Vidal
Background
Stephen Thaler filed patent applications listing an AI system (DABUS) as the sole inventor.
Holding
The Federal Circuit ruled:
Under U.S. law, inventors must be natural persons.
AI cannot be listed as inventor.
Significance for AI-Bioengineering
In AI-assisted therapeutic development:
Human researchers must be named inventors.
The human must contribute to conception.
This case is critical in determining:
Ownership
Inventorship validity
Patent enforceability
8. Amgen Inc. v. Sanofi
Background
Amgen patented a broad class of antibodies defined by function (binding to PCSK9).
Holding
The Court invalidated the patents:
Claims were too broad.
Insufficient enablement — did not teach how to make the full scope.
Key Principle
Broad functional claims require:
Extensive enabling disclosure
Reproducible guidance
Impact on AI-Designed Therapeutics
AI can generate:
Millions of candidate molecules
But claiming:
“All antibodies that bind X protein and lower cholesterol”
is invalid unless:
The patent teaches how to make substantially all of them.
This case reshapes:
AI-generated molecule patents
Functional genus claims
Antibody therapeutics
III. Comparative Patent Framework Overview
| Legal Issue | Governing Principle | Key Case |
|---|---|---|
| GMOs patentability | Human-made organisms are patentable | Chakrabarty |
| Natural phenomena exclusion | Laws of nature not patentable | Mayo |
| Gene isolation | Natural DNA not patentable | Myriad |
| Software abstraction | Abstract ideas not patentable | Alice |
| Diagnostic correlation | Discovery alone insufficient | Ariosa |
| AI inventorship | Inventor must be human | Thaler |
| Functional overbreadth | Must enable full scope | Amgen |
IV. Structural Challenges for AI-Assisted Therapeutics
Abstract Algorithm Problem
AI models risk rejection under Alice.
Natural Law Barrier
Biomarker discoveries risk rejection under Mayo/Ariosa.
Overbreadth Risk
AI enables broad genus claims — risk under Amgen.
Inventorship Complexity
AI as tool vs. AI as inventor (Thaler).
Disclosure Sufficiency
Must describe:
Training data
Model architecture (where required)
Experimental validation
V. Strategic Drafting Approaches
To maximize patent protection in AI-assisted bioengineering:
Claim engineered therapeutic outputs, not correlations.
Emphasize technical improvements in bioengineering processes.
Include experimental validation.
Avoid purely functional genus claims.
Identify clear human inventive contribution.
Provide enabling disclosure for algorithm-generated molecules.
VI. Conclusion
Patent frameworks for AI-assisted bioengineering are shaped by a tension between:
Encouraging innovation in therapeutics
Preventing monopolization of natural laws and abstract ideas
The controlling jurisprudence — especially Chakrabarty, Mayo, Myriad, Alice, Ariosa, Thaler, and Amgen — establishes that:
AI can assist invention.
Natural phenomena cannot be monopolized.
Synthetic bioengineered therapeutics remain patentable.
Human inventorship remains mandatory.
Broad AI-generated functional claims face strict enablement scrutiny.
As AI increasingly drives therapeutic discovery, courts are likely to refine these doctrines further, especially around algorithmic disclosure, AI inventorship, and biologics enablement.
RELATED Blog
comments